Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 299Solid Tumors 184Advanced Solid Tumors 168Solid Tumor 152Mesothelioma, Malignant 152Mesothelioma 121Advanced Solid Tumor 97Carcinoma, Non-Small-Cell Lung 50Retinoblastoma 48Lung Neoplasms 37Solid Tumor, Adult 36Sarcoma 31Ovarian Neoplasms 29Neoplasms 27Stomach Neoplasms 26Carcinoma, Renal Cell 26Small Cell Lung Carcinoma 25Melanoma 25Pancreatic Neoplasms 24Breast Neoplasms 24Unspecified Childhood Solid Tumor, Protocol Specific 23Esophageal Neoplasms 21Uterine Cervical Neoplasms 20Solid Tumours 20Solitary Fibrous Tumor, Pleural 19Osteosarcoma 19Colorectal Neoplasms 17Neuroblastoma 16Head and Neck Neoplasms 16Carcinoma, Hepatocellular 16

Interventions

eribulin 1Irinotecan 1Cefixime 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Relapsed Solid Tumors × Other solid neoplasm × Clear all
NCT02596503 2022-02-15

A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors

University of Colorado, Denver

Phase 1 Completed
2 enrolled
Other solid neoplasm

Relapsed Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡